Trials / Completed
CompletedNCT01515657
Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients
A Randomized, Actively Controlled, Crossover Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Patients With Type II Diabetes
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- PLx Pharma · Industry
- Sex
- All
- Age
- 21 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
This study will determine if aspirin from PL2200, an investigational product, gets into the blood stream as quickly as plain aspirin and enteric coated aspirin, and to test whether PL2200 is able to prevent blood clots as effectively as these other products, when administered to patients with diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PL2200 Aspirin Capsules | 325 mg aspirin; once per day for 3 days |
| DRUG | Immediate-Release Aspirin Tablets | 325 mg aspirin; once per day for 3 days |
| DRUG | Enteric-coated aspirin caplets | 325 mg aspirin; once per day for 3 days |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2012-06-01
- Completion
- 2012-06-01
- First posted
- 2012-01-24
- Last updated
- 2016-03-14
- Results posted
- 2015-09-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01515657. Inclusion in this directory is not an endorsement.